Design Therapeutics Ownership | Who Owns Design Therapeutics?

Design Therapeutics Ownership Summary

Design Therapeutics is owned by 60.70% institutional investors, 35.98% insiders, and 3.33% retail investors. Price t rowe associates inc /md/ is the largest institutional shareholder, holding 12.90% of DSGN shares. Fidelity Select Biotechnology is the top mutual fund, with 1.48% of its assets in Design Therapeutics shares.

DSGN Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Design Therapeutics	60.70%	35.98%	3.33%
Sector	Healthcare Stocks	488.17%	11.08%	-399.26%
Industry	Biotech Stocks	306.59%	11.10%	-217.69%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Price t rowe associates inc /md/	7.29M	12.90%	$705.90M
Logos global management lp	4.22M	7.42%	$14.21M
Durable capital partners lp	3.46M	6.12%	$334.67M
Vanguard group	3.19M	5.65%	$309.29M
Conestoga capital advisors	3.12M	5.52%	$301.76M
Jarislowsky, fraser	2.89M	5.12%	$279.97M
Fiera capital	2.56M	4.53%	$248.02M
Blackrock funding, inc. /de	2.40M	4.21%	$8.07M
Primecap management co/ca/	2.24M	3.96%	$216.78M
Mackenzie financial	2.13M	3.78%	$206.81M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Zeno equity partners llp	266.28K	6.86%	$25.79M
Conestoga capital advisors	3.12M	4.52%	$301.76M
Herald investment management	230.00K	3.65%	$22.24M
Summit creek advisors	258.25K	3.43%	$25.01M
Durable capital partners lp	3.46M	2.75%	$334.67M
Geneva capital management	1.46M	2.57%	$141.16M
Triasima portfolio management	253.85K	2.25%	$24.58M
Pembroke management	125.98K	2.24%	$16.70M
Grandeur peak global advisors	230.82K	1.79%	$22.37M
Jarislowsky, fraser	2.89M	1.70%	$279.97M

Top Buyers

Holder	Shares	% Assets	Change
Congress asset management co /ma	1.22M	0.85%	1.22M
Norges bank	1.12M	0.02%	1.12M
Ubs asset management americas	690.48K	0.02%	690.48K
Blackrock	566.21K	0.00%	213.67K
William blair investment management	212.81K	0.05%	212.81K

Top Sellers

Holder	Shares	% Assets	Change
Arrowstreet capital, limited partnership	611.83K	0.05%	-633.32K
Jarislowsky, fraser	2.89M	1.70%	-438.99K
Ecor1 capital	-	-	-426.68K
T. rowe price investment management	1.70M	0.10%	-379.50K
Price t rowe associates inc /md/	7.29M	0.08%	-313.25K

New Positions

Holder	Shares	% Assets	Change	Value
Congress asset management co /ma	1.22M	0.85%	1.22M	$118.30M
Norges bank	1.12M	0.02%	1.12M	$108.88M
Ubs asset management americas	690.48K	0.02%	690.48K	$66.87M
William blair investment management	212.81K	0.05%	212.81K	$20.61M
Charles schwab investment management	176.46K	0.00%	176.46K	$17.09M

Sold Out

Holder	Change
Fairman group	-8.00
Financial gravity asset management	-11.00
Harbour investments	-12.00
Spire wealth management	-18.00
Clarivest asset management	-22.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2025	90	-8.16%	34,511,542	0.15%	60	1.65%	39	5.41%	33	-17.50%
Mar 31, 2025	2	-99.51%	927,399	-98.96%	1	0.01%	2	-99.00%	-	-100.00%
Dec 31, 2024	414	6.43%	88,660,486	10.86%	156	0.78%	198	13.14%	145	-2.03%
Sep 30, 2024	338	3.68%	65,782,856	-1.17%	116	0.84%	160	-15.34%	126	36.96%
Jun 30, 2024	323	6.60%	66,550,531	2.13%	117	869551.63%	186	8.77%	92	-6.12%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Fidelity Select Biotechnology	839.13K	1.48%	-
Vanguard US Total Market Shares ETF	800.90K	1.41%	-
Vanguard Total Stock Mkt Idx Inv	783.62K	1.38%	-17.28K
iShares Russell 2000 ETF	717.88K	1.26%	-13.65K
Fidelity Small Cap Index	316.43K	0.56%	-
Vanguard Institutional Extnd Mkt Idx Tr	295.05K	0.52%	-131.22K
State St Russell Sm/Mid Cp® Indx NL Cl C	269.86K	0.48%	-
State St Russell Sm/Mid Cp® Indx SL Cl I	269.86K	0.47%	-
iShares Russell 2000 Value ETF	261.75K	0.46%	194.00
iShares Biotechnology ETF	182.77K	0.32%	1.56K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Aug 13, 2025	William Arsani	-	Sell	$1.14M
Aug 13, 2025	William Arsani	-	Sell	$1.81M
Dec 18, 2024	Prasad Deepa	-	Sell	$23.86K
Aug 09, 2024	William Arsani	-	Sell	$3.46M
Mar 22, 2024	Schmid John P.	-	Buy	$33.13K

Insider Transactions Trends

Date	Buy	Sell
2025 Q3	-	2
2025 Q2	-	-
2025 Q1	-	-
2024 Q4	-	1
2024 Q3	-	1

DSGN Ownership FAQ

Who Owns Design Therapeutics?

Design Therapeutics shareholders are primarily institutional investors at 60.70%, followed by 35.98% insiders and 3.32% retail investors. The average institutional ownership in Design Therapeutics's industry, Biotech Stocks , is 306.59%, which Design Therapeutics falls below.

Who owns the most shares of Design Therapeutics?

Design Therapeutics’s largest shareholders are Price t rowe associates inc /md/ (7.29M shares, 12.90%), Logos global management lp (4.22M shares, 7.42%), and Durable capital partners lp (3.46M shares, 6.12%). Together, they hold 26.44% of Design Therapeutics’s total shares outstanding.

Does Blackrock own Design Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Design Therapeutics.

Who is Design Therapeutics’s biggest shareholder by percentage of total assets invested?

Zeno equity partners llp is Design Therapeutics’s biggest shareholder by percentage of total assets invested, with 6.86% of its assets in 266.28K Design Therapeutics shares, valued at 25.79M$.

Who is the top mutual fund holder of Design Therapeutics shares?

Fidelity Select Biotechnology is the top mutual fund holder of Design Therapeutics shares, with 1.48% of its total shares outstanding invested in 839.13K Design Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools